Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

CNBC's Angelica Peebles reports on themes emerging in the pharma space. Republican backs push to repeal part of Trump bill ...

MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond ...

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

Merck & Co. agreed to buy respiratory drugmaker Verona Pharma Plc for around $10 billion as part of its ongoing search for ...

US drugmaker Merck is nearing a deal worth about $10 billion to buy Verona Pharma, a company focused on therapies for lung ...

The deal gives Merck control of Verona’s Ohtuvayre, a newly approved treatment for chronic obstructive pulmonary disease ...